[
    [
        {
            "time": "",
            "orginal_text": "这只白马股竟要摘牌了，背后的43家创投机构炸锅！",
            "features": {
                "keywords": [
                    "白马股",
                    "摘牌",
                    "创投机构"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "这只白马股竟要摘牌了，背后的43家创投机构炸锅！",
            "scores": {
                "News_content": "这只白马股竟要摘牌了，背后的43家创投机构炸锅！",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "速读社丨因医疗器械产品纠纷强生赔偿了67亿 华仁药业拟易主西安国企曲江金控 诉讼纠纷",
            "features": {
                "keywords": [
                    "强生",
                    "赔偿",
                    "华仁药业",
                    "易主",
                    "曲江金控",
                    "诉讼纠纷"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "速读社丨因医疗器械产品纠纷强生赔偿了67亿 华仁药业拟易主西安国企曲江金控 诉讼纠纷",
            "scores": {
                "News_content": "速读社丨因医疗器械产品纠纷强生赔偿了67亿 华仁药业拟易主西安国企曲江金控 诉讼纠纷",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "一家宣布不上市的“白马企业” 套牢了几十家PE、VC",
            "features": {
                "keywords": [
                    "白马企业",
                    "不上市",
                    "PE",
                    "VC"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "一家宣布不上市的“白马企业” 套牢了几十家PE、VC",
            "scores": {
                "News_content": "一家宣布不上市的“白马企业” 套牢了几十家PE、VC",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "维亚生物（1873.HK）: 超额认购106.9倍，我们不一样",
            "features": {
                "keywords": [
                    "维亚生物",
                    "超额认购",
                    "106.9倍"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "维亚生物（1873.HK）: 超额认购106.9倍，我们不一样",
            "scores": {
                "News_content": "维亚生物（1873.HK）: 超额认购106.9倍，我们不一样",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]